Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism
WÜRZBURG, Germany, June 25, 2024 (GLOBE NEWSWIRE) -- Pentixapharm AG, a radiopharmaceutical development company wholly owned by Eckert & Ziegler...